Menu
Recruiting NCT07651891

Evaluation of ALLERgen Specific Vaccination of DOG Allergic Patients in Swedish Practice

Phase IV Interventional Allergic Rhinitis Asthma (Diagnosis)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: ALK Alutard SQ Dog.
Who it may be relevant to
Registry conditions: Allergic Rhinitis, Asthma (Diagnosis). Basic parameters: 18 years — 50 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Sweden
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

STUDY DESIGN A single-center prospective before-and-after study evaluating the effect of Alutard SQ Dog in 40 men and women with moderate-to-severe dog allergy. Participants will serve as their own controls. STUDY OUTLINE The study will begin in the fall of 2026 and will be conducted over a one-year period. At baseline, participants will be asked to record their allergic symptoms, and assessments of lung function and nasal airflow will be performed. Blood samples will also be collected. Following the baseline assessments, participants will undergo allergen provocation by entering a facility containing dogs. After a 30-minute exposure to dogs, participants will again be asked to record their allergic symptoms and will undergo the same assessments performed at baseline. Allergen immunotherapy (AIT) with Alutard SQ Dog will then be initiated according to the standard treatment regimen and continued for one year. At the end of the treatment period, the same provocation procedure and assessments will be repeated. Participants will enter a facility containing dogs, followed by symptom recording and evaluation of lung function, nasal airflow, and relevant laboratory parameters.

Detailed description

* Lung function assessed by Peak Expiratory Flow (PEF) * Nasal airflow assessed by Peak Nasal Inspiratory Flow (PNIF) * Serum levels of allergen-specific IgE to Can f 1, Can f 2, Can f 3, Can f 4, Can f 5, and Can f 6 * Symptom severity assessed using a Visual Analogue Scale (VAS)

Interventions

  • Drug ALK Alutard SQ Dog
    The study is based on Swedish guidelines with an up-titration period of 13 weeks from 100 SQ to 100.000 SQ. The maximum dose of 100.000 SQ is the given every 6-8 weeks for 3 years.

Primary outcome measures

  • Total nasal symptom score (TNSS) [Time frame: Patients will be exposed to dog allergen at baseline and again after one year of treatment with Alutard SQ dog. TNSS will be assessed at both occasions.]
Secondary outcome measures (3)
  • PEF [Time frame: Patients will be exposed to dog allergen at baseline and again after one year of treatment with Alutard SQ dog. Peak expiratory flow will be measuered at both occasions.]
  • PNIF [Time frame: Patients will be exposed to dog allergen at baseline and again after one year of treatment with Alutard SQ dog. PNIF will be measuered at both occasions.]
  • Bloodsample [Time frame: Bloodsample will be taken prior to treatment and after 1 year of treatment]

Eligibility criteria

Inclusion criteria

The subject has provided written informed consent to participate in the study.

  • Age 18-50 years.
  • Moderate-to-severe allergic symptoms upon exposure to dogs.
  • Dog allergy confirmed by positive specific IgE.
  • Considered suitable by the investigator for treatment with Alutard SQ Dog in accordance with the approved Summary of Product Characteristics (SmPC).
  • Female subjects of childbearing potential must use adequate contraception.
  • A negative pregnancy test must be obtained prior to enrolment.

Exclusion criteria

  • Pregnancy or breastfeeding.
  • Autoimmune or connective tissue disease.
  • Cardiovascular disease.
  • Hepatic disease.
  • Renal disease.
  • Malignancy.
  • Upper airway disease (e.g., non-allergic sinusitis or nasal polyposis).
  • Chronic obstructive or restrictive lung disease.
  • Treatment with medications that may interfere with the immune response.
  • Previous immunotherapy or chemotherapy.
  • Significant chronic disease.
  • Major metabolic disease.
  • Alcohol or substance abuse.
  • Mental or cognitive incapacity that may impair compliance with study procedures.
  • Known or suspected hypersensitivity to the study product.
  • Suspected or confirmed bacterial infection.
  • Clinically relevant allergy to house dust mite.
  • Current dog ownership.
  • Any condition that, in the investigator's opinion, may make participation, follow-up, or study assessments inappropriate.
  • Any subject considered unsuitable for enrolment according to the principles of the Declaration of Helsinki.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Sweden · 2 centers
  • Lund University Hospital — Lund
  • Trelleborg Hospital — Trelleborg

Identifiers

NCT: NCT07651891 · CS793

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗